Stockscreener 앱 받기
2.68
4.29%
-0.12
시간 외 거래:
2.86
0.18
+6.72%
전일 마감가:
$2.80
열려 있는:
$2.78
하루 거래량:
719.45K
Relative Volume:
1.22
시가총액:
$165.14M
수익:
$40.37M
순이익/손실:
$-119.72M
주가수익비율:
-1.3136
EPS:
-2.0402
순현금흐름:
$-135.06M
1주 성능:
-13.27%
1개월 성능:
-22.99%
6개월 성능:
-33.50%
1년 성능:
-34.47%
1일 변동 폭
$2.64
$2.79
1주일 범위
$2.64
$3.165
52주 변동 폭
$2.64
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
명칭
Voyager Therapeutics Inc
전화
857-259-5340
주소
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
2.68 | 165.14M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-02 | 개시 | Citigroup | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-10-16 | 개시 | Leerink Partners | Outperform |
| 2024-03-26 | 개시 | Guggenheim | Buy |
| 2024-03-19 | 개시 | H.C. Wainwright | Buy |
| 2024-03-07 | 개시 | Citigroup | Buy |
| 2024-01-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | 개시 | Truist | Buy |
| 2023-03-10 | 개시 | Oppenheimer | Outperform |
| 2021-10-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-02-03 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-24 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-11-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | 개시 | The Benchmark Company | Buy |
| 2020-02-06 | 개시 | Oppenheimer | Outperform |
| 2018-11-15 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-09-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | 개시 | H.C. Wainwright | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-02-02 | 개시 | Morgan Stanley | Overweight |
| 2017-11-28 | 재개 | Piper Jaffray | Overweight |
| 2017-10-31 | 개시 | Robert W. Baird | Outperform |
| 2017-10-27 | 개시 | Canaccord Genuity | Buy |
| 2017-10-23 | 재확인 | Stifel | Buy |
| 2017-10-12 | 개시 | Raymond James | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-28 | 재개 | Stifel | Buy |
모두보기
Voyager Therapeutics Inc 주식(VYGR)의 최신 뉴스
Live Voyager Therapeutics, Inc. (VYGR) Technical Analysis - Traders Union
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Voyager Therapeutics at wells fargo healthcare conference: key data ahead By Investing.com - Investing.com Nigeria
Voyager Therapeutics at wells fargo healthcare conference: key data ahead - Investing.com
Voyager Therapeutics stock holds steady as investors watch gene therapy pipeline - ad-hoc-news.de
Voyager Therapeutics (VYGR) Rises 2.22% as Shares Hold Ground Between $3.29 Support and $3.63 ResistanceInsider Selling Alerts - dars.gov.et
Voyager to Present at Upcoming Investor Conferences - markets.businessinsider.com
Transcript : Voyager Therapeutics, Inc.Special Call - marketscreener.com
Voyager Therapeutics Inc. (VYGR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Composite Profile - siam.in
Voyager Therapeutics Inc. (VYGR) Peer Comparison – Compare with Others - Value Research
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy - Investing.com
Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - Stock Titan
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX) - The Globe and Mail
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - moomoo.com
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus
Voyager Reports Second Quarter 2026 Financial and Operating Results - The Manila Times
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus
Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Voyager Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028 - tradingview.com
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows - TradingView
Voyager Therapeutics (Nasdaq: VYGR) gains FDA IND clearance for VY1706 - Stock Titan
VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION - Moomoo
Voyager Therapeutics (VYGR) Edges Higher by 1.45% as Shares Defend $2.99 SupportFibonacci Arc - dars.gov.et
Voyager Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday - MarketBeat
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VYGR|Voyager Therapeutics Inc|Price:3.090|Chg%:-0.010 - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Cash Flow - TradingKey
TradingKey - TradingKey
Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR - TradingView
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Voyager Therapeutics Inc (VYGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):